Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday

Key Points

• Pliant Therapeutics is expected to report Q1 2026 results before the market opens on Monday, May 11, with analysts forecasting EPS of ($0.36), and an earnings call scheduled for Wednesday, May 13 at 4:00 PM ET.
• In its last report the company posted EPS of ($0.35), beating estimates of ($0.44), but analysts still project roughly ($2) EPS for both the current and next fiscal years.
• Shares trade around $1.21 with a market cap of about $75 million and a 12‑month range of $1.09–$1.95; Wall Street consensus rates the stock as Reduce with a $3.00 target, and institutional investors own approximately 97.3% of the shares.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its earnings results on Wednesday, March 11th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.09. On average, analysts expect Pliant Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pliant Therapeutics Price Performance

NASDAQ PLRX traded up $0.00 on Wednesday, reaching $1.21. 39,475 shares of the company's stock traded hands, compared to its average volume of 689,721. Pliant Therapeutics has a 12 month low of $1.09 and a 12 month high of $1.95. The stock has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $1.36. The stock has a market cap of $75.17 million, a PE ratio of -0.49 and a beta of 1.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rangeley Capital LLC grew its holdings in shares of Pliant Therapeutics by 20.4% in the second quarter. Rangeley Capital LLC now owns 60,220 shares of the company's stock worth $70,000 after purchasing an additional 10,220 shares during the last quarter. Algert Global LLC grew its holdings in shares of Pliant Therapeutics by 17.7% in the third quarter. Algert Global LLC now owns 104,382 shares of the company's stock worth $154,000 after purchasing an additional 15,692 shares during the last quarter. Engineers Gate Manager LP grew its holdings in shares of Pliant Therapeutics by 139.4% in the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company's stock worth $36,000 after purchasing an additional 18,300 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company's stock worth $93,000 after purchasing an additional 20,449 shares during the last quarter. Finally, Jump Financial LLC bought a new position in shares of Pliant Therapeutics in the second quarter worth approximately $30,000. Institutional investors own 97.30% of the company's stock.

Wall Street Analysts Forecast Growth

PLRX has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set a "hold" rating on the stock in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Pliant Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday. Piper Sandler reduced their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set an "overweight" rating on the stock in a research report on Thursday, March 12th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Pliant Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $3.00.

About Pliant Therapeutics

Pliant Therapeutics, Inc NASDAQ: PLRX is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company's lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.